{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:10:06Z","timestamp":1789420206897,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40744-023-00546-0","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T16:02:29Z","timestamp":1681747349000},"page":"825-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02959918","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alan","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"DeHaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Azeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Inshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon S.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas","family":"Nicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi K.","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-5720","authenticated-orcid":false,"given":"Peter G.","family":"Traber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"6","key":"546_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"546_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499\u2013516.","journal-title":"Ann Intern Med"},{"key":"546_CR3","unstructured":"Fernando A, Rednam M, Gujaranthi R, et al. Gout: StatPearls. Treasure Island (FL), 2021."},{"issue":"12","key":"546_CR4","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","volume":"26","author":"RA Brook","year":"2010","unstructured":"Brook RA, Forsythe A, Smeeding JE, Lawrence EN. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010;26(12):2813\u201321.","journal-title":"Curr Med Res Opin"},{"key":"546_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.11604\/pamj.2018.30.64.15292","volume":"30","author":"P Ioannou","year":"2018","unstructured":"Ioannou P, Panagiotakis S. Chronic tophaceous gout. Pan Afr Med J. 2018;30:64.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"546_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","volume":"8","author":"M Francis-Sedlak","year":"2021","unstructured":"Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study. Rheumatol Ther. 2021;8(1):183\u201397.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"546_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"546_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/BOR.0b013e3282f4eff5","volume":"20","author":"E Fels","year":"2008","unstructured":"Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20(2):198\u2013202.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"546_CR9","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58(9):2587\u201390.","journal-title":"Arthritis Rheum"},{"issue":"15","key":"546_CR10","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1096\/fasebj.2.15.3192041","volume":"2","author":"A Varela-Echavarria","year":"1988","unstructured":"Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J. 1988;2(15):3092\u20136.","journal-title":"FASEB J"},{"issue":"3","key":"546_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11926-007-0041-y","volume":"9","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007;9(3):258\u201364.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"546_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"RP Garay","year":"2012","unstructured":"Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9(11):1319\u201323.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"546_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","volume":"18","author":"L Strilchuk","year":"2019","unstructured":"Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Safety. 2019;18(4):261\u201371.","journal-title":"Expert Opin Drug Safety"},{"issue":"5","key":"546_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315\u201329.","journal-title":"BioDrugs"},{"key":"546_CR15","unstructured":"KRYSTEXXA\u00ae (pegloticase) Prescribing Information. 2010. https:\/\/www.hzndocs.com\/KRYSTEXXA-Prescribing-Information.pdf. Accessed Nov 2022."},{"issue":"3","key":"546_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1345\/aph.1Q593","volume":"46","author":"JA Shannon","year":"2012","unstructured":"Shannon JA, Cole SW. Pegloticase: a novel agent for treatment-refractory gout. Ann Pharmacother. 2012;46(3):368\u201376.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"546_CR17","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/art.23810","volume":"58","author":"JS Sundy","year":"2008","unstructured":"Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882\u201391.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"546_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711\u201320.","journal-title":"JAMA"},{"key":"546_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010069.pub3","volume":"8","author":"MK Sriranganathan","year":"2021","unstructured":"Sriranganathan MK, Vinik O, Pardo Pardo J, Bombardier C, Edwards CJ. Interventions for tophi in gout. Cochrane Database Syst Rev. 2021;8: CD010069. https:\/\/doi.org\/10.1002\/14651858.CD010069.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"546_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3899\/jrheum.200460","volume":"48","author":"JK Botson","year":"2021","unstructured":"Botson JK, Tesser JRP, Bennett R, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48(5):767\u201374.","journal-title":"J Rheumatol"},{"key":"546_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","volume":"11","author":"TK Kishimoto","year":"2020","unstructured":"Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020;11:969.","journal-title":"Front Immunol"},{"issue":"5","key":"546_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/oxfordjournals.jbchem.a021514","volume":"120","author":"Y Koyama","year":"1996","unstructured":"Koyama Y, Ichikawa T, Nakano E. Cloning, sequence analysis, and expression in Escherichia coli of the gene encoding the Candida utilis urate oxidase (uricase). J Biochem. 1996;120(5):969\u201373.","journal-title":"J Biochem"},{"issue":"9","key":"546_CR23","first-page":"1942","volume":"29","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002;29(9):1942\u20139.","journal-title":"J Rheumatol"},{"issue":"10","key":"546_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nnano.2016.135","volume":"11","author":"TK Kishimoto","year":"2016","unstructured":"Kishimoto TK, Ferrari JD, LaMothe RA, et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 2016;11(10):890\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"546_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","volume":"13","author":"E Sands","year":"2022","unstructured":"Sands E, Kivitz A, DeHaan W, Leung SS, Johnston L, Kishimoto TK. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat Commun. 2022;13(1):272.","journal-title":"Nat Commun"},{"key":"546_CR26","unstructured":"DeHaan W KA, Azeem R. Monthly dosing of ImmTOR tolerogenic nanoparticles combined with pegylated uricase (Pegadricase) mitigates formation of anti-drug antibodies resulting in sustained uricase activityin symptomatic gout patients. Abstract 1235. Arthritis Rheumatol. 2019:71(Suppl 10)."},{"issue":"2","key":"546_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.mce.2012.10.030","volume":"365","author":"MJ Pereira","year":"2013","unstructured":"Pereira MJ, Palming J, Rizell M, et al. The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. Mol Cell Endocrinol. 2013;365(2):260\u20139.","journal-title":"Mol Cell Endocrinol"},{"key":"546_CR28","doi-asserted-by":"publisher","first-page":"9669","DOI":"10.2147\/OTT.S195121","volume":"12","author":"C Arena","year":"2019","unstructured":"Arena C, Troiano G, Zhurakivska K, Nocini R, Lo ML. Stomatitis and everolimus: a review of current literature on 8,201 patients. Onco Targets Ther. 2019;12:9669\u201383.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"546_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","volume":"6","author":"SA Soefje","year":"2011","unstructured":"Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6(2):125\u20139.","journal-title":"Target Oncol"},{"issue":"2","key":"546_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","volume":"6","author":"RT Keenan","year":"2019","unstructured":"Keenan RT, Baraf HSB, LaMoreaux B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol Ther. 2019;6(2):299\u2013304.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"546_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"546_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken). 2014;66(10):1551\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"14","key":"546_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2147\/TCRM.S162956","volume":"3","author":"F Perez-Ruiz","year":"2018","unstructured":"Perez-Ruiz F, Desideri G. Improving adherence to gout therapy. Ther Clin Risk Manag. 2018;3(14):793\u2013802.","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"546_CR34","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. NEJM. 2019;380(8):752\u201362.","journal-title":"NEJM"},{"issue":"4","key":"546_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10067-020-05363-2","volume":"40","author":"V Valerio","year":"2021","unstructured":"Valerio V, Kwok M, Loewen H, et al. Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clin Rheumatol. 2021;40(4):1259\u201371.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"546_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00302669","volume":"14","author":"A Schnabel","year":"1994","unstructured":"Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg\/week for rheumatoid arthritis. Rheumatol Int. 1994;14(1):33\u20138.","journal-title":"Rheumatol Int"},{"issue":"1","key":"546_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","volume":"69","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis. 2010;69(1):43\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00546-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T17:41:52Z","timestamp":1688665312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00546-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00546-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}